Werewolf Therapeutics, Inc.
$0.97
▲
5.38%
2026-04-21 07:20:01
werewolftx.com
NMS: HOWL
Explore Werewolf Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$45.96 M
Current Price
$0.97
52W High / Low
$2.38 / $0.53
Stock P/E
—
Book Value
$0.51
Dividend Yield
—
ROCE
-182.5%
ROE
-1.24%
Face Value
—
EPS
$-1.33
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.54
Debt / Equity
38.04
Current Ratio
1.62
Quick Ratio
1.62
Forward P/E
-0.86
Price / Sales
—
Enterprise Value
$-6.36 M
EV / EBITDA
0.11
EV / Revenue
—
Rating
Strong Buy
Target Price
$7
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Crinetics Pharmaceuticals, Inc. | $40.25 | — | $4.21 B | — | -49.63% | -40.17% | $57.99 / $25.83 | $10.38 |
| 2. | LB Pharmaceuticals Inc | $31.67 | — | $875.16 M | — | -9.95% | -15.7% | $30.72 / $13.36 | $11.91 |
| 3. | Lexaria Bioscience Corp. | $0.99 | — | $25.53 M | — | -443.04% | -1.55% | $1.69 / $0.46 | $0.22 |
| 4. | PMGC Holdings Inc. | $3.32 | — | $6.35 M | — | -76.42% | -1.07% | $309.12 / $1.62 | $97.11 |
| 5. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 6. | Spero Therapeutics, Inc. | $2.84 | 19.18 | $164.41 M | — | 11.92% | 16.3% | $3.22 / $0.57 | $1.05 |
| 7. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.42 M | -15.73 M | -17.54 M | -17.99 M | -20.35 M | — |
| Net Profit | -8.38 M | -16.37 M | -17.98 M | -18.09 M | -20.4 M | — |
| EPS in Rs | -0.17 | -0.34 | -0.37 | -0.37 | -0.42 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 1.89 M | 19.94 M | 16.4 M |
| Operating Profit | -60.68 M | -73.59 M | -40.5 M | -56.06 M |
| Net Profit | -60.82 M | -70.52 M | -37.37 M | -53.81 M |
| EPS in Rs | -1.25 | -1.45 | -0.77 | -1.11 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 69.4 M | 126.93 M | 174.83 M | 160.25 M |
| Total Liabilities | 44.59 M | 53.54 M | 63.46 M | 37.91 M |
| Equity | 24.8 M | 73.39 M | 111.37 M | 122.34 M |
| Current Assets | 58.59 M | 113.07 M | 138.37 M | 140.2 M |
| Current Liabilities | 36.15 M | 15.18 M | 19.38 M | 23.99 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -60.29 M | -56.19 M | -32.61 M | -40.6 M |
| Investing CF | 0 M | -0.25 M | -0.77 M | -3.61 M |
| Financing CF | 6.03 M | 13.08 M | 58.43 M | 15.91 M |
| Free CF | -60.29 M | -56.44 M | -33.38 M | -44.21 M |
| Capex | — | -0.25 M | -0.77 M | -3.61 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -90.55% | 21.6% | — | — |
| Earnings Growth % | -88.7% | 30.56% | — | — |
| Profit Margin % | -3740.85% | -187.37% | -328.09% | — |
| Operating Margin % | -3904.19% | -203.09% | -341.78% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -3397.61% | -162.79% | -321.36% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.